| 27.8 -0.05 (-0.18%) | 09-10 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 33.15  |
1-year : | 35.29 |
| Resists | First : | 28.38 |
Second : | 30.21 |
| Pivot price | 28.23 |
|||
| Supports | First : | 25.42 |
Second : | 21.14 |
| MAs | MA(5) : | 27.62 |
MA(20) : | 28.28 |
| MA(100) : | 25.89 |
MA(250) : | 20.43 |
|
| MACD | MACD : | -0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 27.3 |
D(3) : | 26.6 |
| RSI | RSI(14): 49 |
|||
| 52-week | High : | 33.77 | Low : | 6.57 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ DNTH ] has closed above bottom band by 34.7%. Bollinger Bands are 48.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 28.63 - 28.78 | 28.78 - 28.9 |
| Low: | 27.25 - 27.4 | 27.4 - 27.53 |
| Close: | 27.58 - 27.82 | 27.82 - 28.01 |
Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.
Wed, 04 Sep 2024
Dianthus Therapeutics to Participate in Three Healthcare Investor Conferences in September - StockTitan
Sun, 01 Sep 2024
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Sees Large Growth in Short Interest - MarketBeat
Tue, 27 Aug 2024
Dianthus Therapeutics (NASDAQ:DNTH) Shares Down 4.7% - MarketBeat
Mon, 26 Aug 2024
Dianthus Therapeutics (NASDAQ:DNTH) Sees Unusually-High Trading Volume - MarketBeat
Sat, 24 Aug 2024
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Average Rating of "Buy" by Brokerages - MarketBeat
Mon, 29 Jul 2024
Dianthus: Improved Autoimmune Disorder Targeting With Classical Pathway Inhibition (DNTH) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 29 (M) |
| Held by Insiders | 1.333e+007 (%) |
| Held by Institutions | 5.1 (%) |
| Shares Short | 3,340 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -6.868e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 191.8 % |
| Return on Equity (ttm) | -19.9 % |
| Qtrly Rev. Growth | 4.12e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -51 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 4.06e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|